Phase II Study of Olaparib in Combination With Pembrolizumab in Patients With Advanced Melanoma With Homologous Recombination (HR) Pathway Gene Mutation
This study is testing a combination of two medications, olaparib and pembrolizumab, for advanced skin cancer (melanoma). It aims to help patients whose cancer has specific gene changes and has continued to grow despite standard treatments.
You may be eligible if you have advanced melanoma with a specific DNA repair gene mutation, and your previous treatments have stopped working or were too hard to tolerate. You also need to be well enough to go about your daily activities.
Participants will receive a combination of olaparib, a targeted medication, and pembrolizumab, an immunotherapy drug that helps your immune system fight the cancer. Your health and tumor size will be closely monitored through regular scans and check-ups.
The study has locations in San Francisco, California, and Houston, Texas, and its current recruitment status is unknown.
- 1Tests a combination of two cancer-fighting drugs: olaparib and pembrolizumab
- 2Designed for patients with advanced melanoma and a specific gene mutation
- 3For individuals whose previous treatments have stopped working
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.